1 day Ago By ABMN Staff
Relmada Therapeutics ( NASDAQ:RLMD – Get Free Report ) was upgraded by investment analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a report issued on Tuesday, MarketBeat Ratings reports. The firm currently has a $13.00 price objective on the stock, up from their prior price objective of $3.
50. Jefferies Financial Group’s target price points to a potential upside of 272.49% from the stock’s previous close.
Separately, The Goldman Sachs Group downgraded shares of Relmada Therapeutics from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $3.00 to $2.00 in a research note on Wednesday, June 5th.
Check Out Our Latest Report on Relmada Therapeutics Relmada Therapeutics Stock Performance Relmada Therapeutics ( NASDAQ:RLMD – Get Free Report ) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.
83) by $0.24. During the same quarter in the prior year, the business posted ($0.
84) EPS. Sell-side analysts forecast that Relmada Therapeutics will post -2.39 earnings per share for the current year.
Insiders Place Their Bets In other news, CEO Sergio Traversa acquired 51,407 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was purchased at an average price of $2.99 per share, for a total transaction of $153,706.
93. Following the completion of the transaction, the chief executive officer now directly owns 384,024 shares in the company, valued at approximately $1,148,231.76.
The acquisition was disclosed in a filing with the SEC, which is available through this link . In other Relmada Therapeutics news, CFO Maged Shenouda bought 24,120 shares of Relmada Therapeutics stock in a transaction on Wednesday, September 11th. The shares were acquired at an average price of $2.
95 per share, for a total transaction of $71,154.00. Following the completion of the purchase, the chief financial officer now directly owns 88,335 shares in the company, valued at approximately $260,588.
25. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link . Also, CEO Sergio Traversa bought 51,407 shares of the firm’s stock in a transaction on Wednesday, September 11th.
The shares were purchased at an average cost of $2.99 per share, with a total value of $153,706.93.
Following the completion of the transaction, the chief executive officer now owns 384,024 shares in the company, valued at $1,148,231.76. The disclosure for this purchase can be found here .
Insiders bought a total of 152,300 shares of company stock worth $429,655 over the last three months. 18.00% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Relmada Therapeutics Hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC lifted its stake in shares of Relmada Therapeutics by 1.0% during the second quarter.
Acadian Asset Management LLC now owns 1,193,333 shares of the company’s stock worth $3,577,000 after buying an additional 12,147 shares during the period. Opaleye Management Inc. increased its stake in shares of Relmada Therapeutics by 2,823.
3% in the fourth quarter. Opaleye Management Inc. now owns 877,000 shares of the company’s stock worth $3,631,000 after acquiring an additional 847,000 shares during the period.
Vestal Point Capital LP purchased a new position in shares of Relmada Therapeutics during the fourth quarter worth $476,000. AdvisorShares Investments LLC raised its position in Relmada Therapeutics by 28.5% during the second quarter.
AdvisorShares Investments LLC now owns 90,028 shares of the company’s stock valued at $276,000 after acquiring an additional 19,975 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Relmada Therapeutics by 153.6% in the 2nd quarter.
Renaissance Technologies LLC now owns 88,775 shares of the company’s stock valued at $266,000 after purchasing an additional 53,767 shares during the period. 45.24% of the stock is currently owned by hedge funds and other institutional investors.
Relmada Therapeutics Company Profile ( Get Free Report ) Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. See Also Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
